Danish 4.5 mg Zinc Gluconate Lozenge Study
Chapter 4.A.4. - Danish 4.5 mg Zinc Gluconate Lozenge Study

During the winter of 1987-1988, 463 volunteers were enrolled in a zinc gluconate lozenge study at Bispebjerg Hospital in Copenhagen, Denmark.(15) Very low dose, non-astringent zinc gluconate lozenges were found ineffective compared to placebo in treating natural common colds in this double-blind study. Lozenges contained 4.5 mg zinc in a flavored, hard-boiled maltitol-syrup candy. Extreme bitterness caused the researchers to use the very low dosage. Maltitol is a liquid food ingredient consisting of 75 percent dry substance containing 72-73 percent hydrogenated disaccharides, a maximum of 8 percent D-sorbitol and with approximately 20 percent of the hydrogenated disaccharides having a degree of polymerization higher than 2.(16) Hard-boiled maltitol syrup based lozenges were manufactured by Alfred Benzon Company in Hvidovre.

Volunteers were to use one lozenge each 1 to 1.5 hours (12 t/d), starting immediately after the first symptom of a common cold appeared. Similar 7.5-mg zinc lozenges produced a salivary average concentration of 1.4 to 4.4 mMol of zinc gluconate.

Results of Study

Durations of colds were evaluated by the Mantel-Cox test, with cessation of symptoms considered as the end-point. One hundred-thirty patients completed the study, with 69 patients receiving zinc and 61 receiving placebo. No statistically significant differences were found between the two groups with regard to age, sex, smoking, or severity of symptoms at the start of the study. Durations of common colds were virtually identical in zinc and placebo groups, with only minor fluctuations occurring. During the first four days, no differences in duration occurred. From day 5 through day 8, the placebo-treated group fared slightly better than the zinc-treated group.

No improvement from ZIA 25 lozenges

Figure 8. Effect of very low dosage ZIA 13.4 zinc gluconate and placebo lozenges (courtesy of Weismann, and Danish Medical Bulletin).

No over-all improvement in severity of symptoms occurred. No statistically significant difference occurred in side effects between the groups, although three out of 61 receiving zinc lozenges noted an unpleasant taste. Lozenges were generally well tolerated by all patients. No significant change in serum zinc occurred with the use of 12 lozenges per day.

Zinc Ion Availability

ZIA values for these lozenges can only be estimated. All that is known is there was 4.5 mg of zinc as zinc gluconate in maltitol lozenges taken 12 times/day. If lozenges required 15 minutes to dissolve (a figure applicable to several commercial zinc lozenge products), and 17 ml of zinc-laden saliva was generated (also reasonable for lozenges), ZIA calculation results in a value of 13.4. Zn2+ ion salivary concentration was 1.5 mMol or less at 7.4 pH (see Figure 1 in Chapter 1). Zinc gluconate over-all salivary concentration was reported to be 4.4 to 5.0 mMol.

As ZIA value was estimated to be only 13.4 percent as high as the original 1984 Eby lozenges, one can reasonably conclude low ZIA value was responsible for failure in this study. Flavor was considered acceptable and was probably not a consideration in lozenge failure, primarily because zinc content had been greatly lowered to arrive at a reasonably pleasant taste. For example, raising zinc to 7.5 mg resulted in an unacceptable taste in the maltitol tablet base.

Chapter 4.B. - Effects of Strong Zinc Complexes on Duration of Common Colds